Ligand Pharmaceuticals (LGND) Income from Non-Controlling Interests (2014 - 2015)
Ligand Pharmaceuticals recorded quarterly Income from Non-Controlling Interests of -$1.5 million in Q2 2015, down 82.33% quarter-over-quarter from -$843000.0 in Q1 2015, and down 405.59% year-over-year from $502958.0 in Q2 2014.
Ligand Pharmaceuticals' Income from Non-Controlling Interests history runs 2 years deep, the most recent figure standing at -$1.5 million for Q2 2015.
- In Q2 2015, Income from Non-Controlling Interests fell 405.59% year-over-year to -$1.5 million; the TTM figure through Mar 2016 stood at -$1.5 million (up 22.18% YoY), while the FY2015 annual figure was $2.4 million, up 310.25% from the prior year.
- Income from Non-Controlling Interests came in at -$1.5 million for Q2 2015 at Ligand Pharmaceuticals, down from -$843000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of -$304000.0 in Q2 2014 to a low of -$1.5 million in Q2 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.75 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Ligand Pharmaceuticals | 4.61 Bn | 3.83 Bn | 48.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2015 | -1.54 Mn |
| Mar 31, 2015 | -843,000.00 |
| Dec 31, 2014 | -325,000.00 |
| Sep 30, 2014 | -503,000.00 |
| Jun 30, 2014 | -304,000.00 |